Company Overview: AIMT

Upcoming Projects (AIMT)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (AIMT)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (AIMT)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (AIMT)

Aimmune's (AIMT) AR101 Peanut Allergy Phase 3 data to be presented February 24 at AAAAI Annual Meeting.
Ticker: AIMT
Occurred on: Feb 25, 2019
Aimmune (AIMT) to File Investigational New Drug Application for Egg Allergy in 2018
Ticker: AIMT
Occurred on: Dec 20, 2018
Top-Line Data Expected in Q4 2017 for Aimmune's (AIMT) Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies
Ticker: AIMT
Occurred on: Feb 20, 2018
Phase 3 PALISADE trial of AR101 for Peanut Allergy to be completed Q4 2017
Ticker: AIMT
Occurred on: Feb 20, 2018
Aimmune (AIMT) to Initiate Pediatric Study ARC005 in Children Ages 1-3 for AR101 in Peanut Allergies in H2 2017
Ticker: AIMT
Occurred on: Jul 05, 2017
Aimmune (AIMT) Will Begin Enrollment for RAMSES Trial Designed to Build Real-World Experience with AR101 in Desensitization of Peanut Allergies in the Q2 2017
Ticker: AIMT
Occurred on: May 11, 2017
Aimmune (AIMT) to Complete Up-dosing of Peanut Allergy Patients Taking AR101 in Phase 3 PALISADE Trial in H1 2017
Ticker: AIMT
Occurred on: Mar 06, 2017
Aimmune Therapeutics (AIMT) Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Ticker: AIMT
Occurred on: Mar 06, 2017
Aimmune Therapeutics (AIMT) Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
Ticker: AIMT
Occurred on: Feb 16, 2017
Aimmune (AIMT) Expects to Begin Open-Label Rollover Trial From PALISADE in Q4 2016 Evaluating AR101 in Treatment of Peanut Allergies: Follow-on Study named ARC004
Ticker: AIMT
Occurred on: Dec 08, 2016
Aimmune (AIMT) Completes Enrollment for Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies
Ticker: AIMT
Occurred on: Nov 28, 2016
Aimmune (AIMT) Expects to Complete Enrollment for Phase 3 PALISADE Trial Evaluating AR101 in Peanut Allergies in H2 2016
Ticker: AIMT
Occurred on: Sep 20, 2016
Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy
Ticker: AIMT
Occurred on: Jun 13, 2016
Target enrollment of 500 patients in AR101 PALISADE Phase 2 studies is on track to complete in the second half of this year, and we expect top-line data in the second half of 2017
Ticker: AIMT
Occurred on: May 16, 2016
Aimmune (AIMT) Announces Phase 2 ARC002 Data Evaluating AR101 in Treatment of Peanut Allergy
Ticker: AIMT
Occurred on: Mar 06, 2016
Aimmune (AIMT) Initiates Enrollment for Phase 3 PALISADE Trial Evaluating AR101 in Patients With Peanut Allergies
Ticker: AIMT
Occurred on: Jan 11, 2016

Strategic Initiatives (AIMT)

Aimmune (AIMT) Announces $145MM Investment From Nestle Health Science (NSRGY) as Part of Two-Year Collaboration Agreement to Develop Food Allergy Therapies
Tickers: NSRGY, AIMT
Announcement Date: Nov 04, 2016

AIMT Overview